Figure 1
Figure 1. Outcome of limited stage NLPHL. (A) Era-to-era comparison of TTP of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0074). (B) Era-to-era comparison of PFS of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0024). (C) Era-to-era comparison of OS limited-stage NLPHL patients treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .074).

Outcome of limited stage NLPHL. (A) Era-to-era comparison of TTP of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0074). (B) Era-to-era comparison of PFS of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0024). (C) Era-to-era comparison of OS limited-stage NLPHL patients treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .074).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal